Treatment Action Group analysis finds global TB R&D rose by just 2% from 2009: Less than one-third of the global need.

There is currently insufficient evidence to adopt new case definitions for drug-resistant TB.

Childhood TB is a hidden epidemic

Against a backdrop of growing concern about the impact of tuberculosis on children, top scientific experts today published a global plan of action for developing the vaccines that are seen as critical to eliminating the disease.

Today, the U.S. Agency for International Development (USAID) released its annual report to Congress on U.S. Government (USG) international foreign assistance for tuberculosis (TB) control.

Goal is to find new treatment that takes months, not years, and cures multiple forms of tuberculosis.

Alarming new data suggest that the global scope of multidrug-resistant tuberculosis (MDR-TB) is much more vast than previously estimated, requiring a concerted international effort to combat this deadlier form of the disease, the medical humanitarian organization Médecins Sans Frontières (MSF) announced today.

Tuberculosis on the retreat in Europe but concerns about drug-resistant TB and treatment failure remain.

The HIV/TB study showes that 30% of people living with HIV in the Eastern European region also suffering from TB, die within 12 months after the diagnosis, and most of them die from TB. The development of MDR-TB is a huge problem not only for the people living with HIV, but also for the rest of the population in the region and in the rest of Europe.

The Stop TB Partnership Working Group on New TB Vaccines presents the Tuberculosis Vaccine Candidates 2011, as an update of the 2009 Pipeline.